News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Putney, Inc. Names Bert Mileski as Vice President of Quality


4/11/2012 8:45:25 AM

PORTLAND, Maine, April 10, 2012 /PRNewswire/ -- Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, announced today that Bert Mileski has joined the company's senior leadership team as Vice President of Quality, reporting directly to Putney's CEO and president, Jean Hoffman. Mileski's extensive experience in the human generic industry includes 12 years at Barr Laboratories, overseeing that company's quality operations during its explosive growth from $300million to $3billion in sales. In his new position with Putney, Mileski will assume immediate responsibility for strategic leadership and execution of Putney's quality assurance programs as it ramps up both its R&D and commercial manufacturing operations.

Hoffman says that Mileski's deep understanding of pharmaceutical manufacturing, quality assurance and regulatory compliance, as well as his track record of excellence at Barr, take Putney to a new level in both quality systems and manufacturing. "As we put more high quality generic drugs for pets into our pipeline and commercialize our FDA Center for Veterinary Medicine (CVM)-approved drugs, our uncompromising commitment to quality remains critical to our success. Bert's demonstrated leadership and thorough knowledge of FDA regulations and current Good Manufacturing Practices (cGMP) will help Putney meet timelines and deliver on its goals," says Hoffman.

Putney board member and former CEO of Barr Pharmaceuticals, Bruce Downey, says that Mileski will play a critical role during Putney's next stage of dramatic growth. "As Vice President of Quality for Barr's US Operations, Bert was instrumental in forging and maintaining our excellent FDA-compliance record. He understands how to build quality into a system to prevent compliance, manufacturing and supply chain issues," says Downey.

Mileski, who has been working with Putney as a consultant, says Putney is well-positioned to succeed in the pet pharmaceutical marketplace. "I'm excited to be part of this talented team that is both passionate and capable. As Putney continues to grow, I look forward to managing the quality systems and providing the technical expertise that ensures our customers get a steady supply of quality products at an affordable price," says Mileski.

About Putney
Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney's ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.

SOURCE Putney, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES